VTRS
Price
$9.12
Change
-$0.13 (-1.41%)
Updated
Jul 11 closing price
Capitalization
14.18B
25 days until earnings call
ZTS
Price
$154.96
Change
-$3.84 (-2.42%)
Updated
Jul 11 closing price
Capitalization
77.48B
23 days until earnings call
Interact to see
Advertisement

VTRS vs ZTS

Header iconVTRS vs ZTS Comparison
Open Charts VTRS vs ZTSBanner chart's image
Viatris
Price$9.12
Change-$0.13 (-1.41%)
Volume$7.11M
Capitalization14.18B
ZOETIS
Price$154.96
Change-$3.84 (-2.42%)
Volume$2.27M
Capitalization77.48B
VTRS vs ZTS Comparison Chart in %
Loading...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
VTRS vs. ZTS commentary
Jul 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VTRS is a Hold and ZTS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 13, 2025
Stock price -- (VTRS: $9.12 vs. ZTS: $154.96)
Brand notoriety: VTRS: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: VTRS: 49% vs. ZTS: 75%
Market capitalization -- VTRS: $14.18B vs. ZTS: $77.48B
VTRS [@Pharmaceuticals: Other] is valued at $14.18B. ZTS’s [@Pharmaceuticals: Other] market capitalization is $77.48B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

VTRS’s FA Score shows that 2 FA rating(s) are green whileZTS’s FA Score has 1 green FA rating(s).

  • VTRS’s FA Score: 2 green, 3 red.
  • ZTS’s FA Score: 1 green, 4 red.
According to our system of comparison, VTRS is a better buy in the long-term than ZTS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

VTRS’s TA Score shows that 3 TA indicator(s) are bullish while ZTS’s TA Score has 2 bullish TA indicator(s).

  • VTRS’s TA Score: 3 bullish, 4 bearish.
  • ZTS’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, VTRS is a better buy in the short-term than ZTS.

Price Growth

VTRS (@Pharmaceuticals: Other) experienced а -2.15% price change this week, while ZTS (@Pharmaceuticals: Other) price change was -2.65% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +53.35%. For the same industry, the average monthly price growth was +4.99%, and the average quarterly price growth was +71.83%.

Reported Earning Dates

VTRS is expected to report earnings on Nov 10, 2025.

ZTS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+53.35% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($77.5B) has a higher market cap than VTRS($14.2B). VTRS has higher P/E ratio than ZTS: VTRS (238.80) vs ZTS (32.94). ZTS YTD gains are higher at: -4.282 vs. VTRS (-24.762). ZTS (3.67B) and VTRS (3.52B) have comparable annual earnings (EBITDA) . ZTS has more cash in the bank: 2.04B vs. VTRS (1.18B). ZTS has less debt than VTRS: ZTS (6.76B) vs VTRS (18.4B). VTRS has higher revenues than ZTS: VTRS (15.4B) vs ZTS (8.54B).
VTRSZTSVTRS / ZTS
Capitalization14.2B77.5B18%
EBITDA3.52B3.67B96%
Gain YTD-24.762-4.282578%
P/E Ratio238.8032.94725%
Revenue15.4B8.54B180%
Total Cash1.18B2.04B58%
Total Debt18.4B6.76B272%
FUNDAMENTALS RATINGS
VTRS vs ZTS: Fundamental Ratings
VTRS
ZTS
OUTLOOK RATING
1..100
8382
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
65
Fair valued
PROFIT vs RISK RATING
1..100
10078
SMR RATING
1..100
9419
PRICE GROWTH RATING
1..100
5050
P/E GROWTH RATING
1..100
175
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (14) in the null industry is somewhat better than the same rating for ZTS (65) in the Pharmaceuticals Generic industry. This means that VTRS’s stock grew somewhat faster than ZTS’s over the last 12 months.

ZTS's Profit vs Risk Rating (78) in the Pharmaceuticals Generic industry is in the same range as VTRS (100) in the null industry. This means that ZTS’s stock grew similarly to VTRS’s over the last 12 months.

ZTS's SMR Rating (19) in the Pharmaceuticals Generic industry is significantly better than the same rating for VTRS (94) in the null industry. This means that ZTS’s stock grew significantly faster than VTRS’s over the last 12 months.

ZTS's Price Growth Rating (50) in the Pharmaceuticals Generic industry is in the same range as VTRS (50) in the null industry. This means that ZTS’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is significantly better than the same rating for ZTS (75) in the Pharmaceuticals Generic industry. This means that VTRS’s stock grew significantly faster than ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
VTRSZTS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
52%
Bearish Trend 3 days ago
63%
Momentum
ODDS (%)
Bullish Trend 3 days ago
59%
Bearish Trend 3 days ago
57%
MACD
ODDS (%)
Bearish Trend 3 days ago
62%
Bearish Trend 3 days ago
62%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
65%
Bearish Trend 3 days ago
56%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
61%
Bearish Trend 3 days ago
58%
Advances
ODDS (%)
Bullish Trend 4 days ago
67%
Bullish Trend 4 days ago
58%
Declines
ODDS (%)
Bearish Trend 7 days ago
66%
Bearish Trend 18 days ago
55%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
60%
Bullish Trend 3 days ago
59%
Aroon
ODDS (%)
Bullish Trend 3 days ago
62%
Bearish Trend 3 days ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PSLV12.950.35
+2.78%
Sprott Physical Silver Trust
WUGI81.390.02
+0.03%
AXS Esoterica NextG Economy ETF
FDRR55.28-0.17
-0.30%
Fidelity Dividend ETF for Rising Rates
OCCI6.27-0.03
-0.48%
OFS Credit Company
DRAI27.99-0.20
-0.69%
Draco Evolution AI ETF